British regulators have granted permission for human trials of an experimental Ebola vaccine developed at the University of Oxford, approximately eight weeks after a public health emergency was declared. The trial represents the first of four vaccines under development to advance to clinical testing phases.
The current Ebola outbreak, primarily affecting the Democratic Republic of the Congo, has resulted in 625 deaths and 1,792 confirmed cases to date. The outbreak is caused by the Bundibugyo species of Ebola, which differs from other known Ebola variants and requires distinct treatment and vaccine approaches. The epidemic continues to spread in a conflict zone with highly mobile populations, creating urgency for vaccine development.
The Oxford trial will involve 50 healthy adults aged 18-55, with initial doses anticipated within weeks. Researchers are simultaneously preparing for additional trials in Uganda and other African locations. The vaccine employs a modified adenovirus technology previously used in Covid-19 vaccines, allowing rapid development timelines. The approach uses a genetically altered chimpanzee cold virus as a delivery mechanism, with genetic material from the Bundibugyo Ebola species inserted to trigger immune responses. The Serum Institute of India has manufactured approximately 620,000 doses to clinical standards.
Vaccine development typically requires up to a decade, but researchers report maintaining standard safety protocols while conducting multiple testing phases simultaneously across different facilities. Monitoring of trial participants will continue for one year, though immune response data may emerge more quickly. Scientists acknowledge potential side effects based on experiences with previous vaccines, though they emphasize that risks from the vaccine are considerably lower than the fatality rate of the Bundibugyo variant, which kills approximately one-third of infected individuals.
Three additional vaccine candidates are in development, including options from Moderna using mRNA technology and approaches from the International Aids Vaccine Initiative and Public Health Vaccines.
Article Attribution | Read More at Article Source
Article summary produced by Claude AI